164 filings
Page 5 of 9
6-K
ye7ptdzpllfjm2lvk
18 Jun 18
Current report (foreign)
9:52am
6-K
1wm3yg75fx
15 Jun 18
Current report (foreign)
12:00am
6-K
zrev8brfxpb nswk
14 Jun 18
Current report (foreign)
12:00am
6-K
67hmgi
7 Jun 18
Trillium Therapeutics Appoints Yaping Shou, MD, PHD As Chief Medical Officer
7:02am
6-K
lofm t8a8q1
5 Jun 18
Current report (foreign)
12:00am
6-K
wab8j
11 May 18
Interim Condensed Consolidated Financial Statements
7:05am
6-K
zi0p ivb3w
18 Apr 18
Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 Aacr Annual Meeting
12:00am
6-K
t4q1mzjy 5pjt
12 Apr 18
Trillium Therapeutics to Report Preclinical Data on TTI-621 and TTI-622 at the Aacr Annual Meeting 2018
12:00am
6-K
w1o 4dunacm4rt3
10 Apr 18
Current report (foreign)
12:00am
6-K
u1jjgo4gg2r3ztkqf8y9
20 Mar 18
Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-cell Lymphoma
12:00am
6-K
8eyo fj75qu6zyt
9 Mar 18
Trillium Therapeutics Reports Annual 2017 Financial and Operating Results
12:00am
6-K
ih7m 1lhawxha5j
9 Feb 18
Trillium Therapeutics to Present at Investor and Scientific Conferences In the First Quarter
12:00am
6-K
xdho m3dvx8
17 Jan 18
Current report (foreign)
12:00am
6-K
y1189s
11 Dec 17
Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59TH Annual Meeting
12:00am
6-K
7tbjf6qynldtq4 voyh1
4 Dec 17
Trillium Announces Closing of Private Placement
12:00am
6-K
ybp91a
20 Nov 17
Trillium Therapeutics’ TTI-2341 Egfr Inhibitor Program Featured at the Society for Neuro-oncology 22ND Annual Meeting
12:00am
6-K
80bid4t omater0zoyt
15 Nov 17
Trillium Announces Private Placement
12:00am
6-K
d9liqcan ufcih
15 Nov 17
Current report (foreign)
12:00am
6-K
2wuk0kn
13 Nov 17
Interim Condensed Consolidated Financial Statements
12:00am
6-K
ve2oyk43cww wu7vn1h
13 Nov 17
Current report (foreign)
12:00am